



The 6th Congress of Asian Society for Pediatric Research & 51st Annual Meeting of Taiwan Pediatric Association

April 15-18, 2010 Taipei, Taiwan



DAVID P. SPEERT

Institution:	University of British Columbia
Title:	Professor and Head, Division of Infectious and Immunological Diseases, Dept of Pediatrics, University of British Columbia
Tel No.:	+604 875-2438
Fax No.:	+604 875-2226
E-mail:	dspeert@cw.bc.ca
Address:	Room 377, Research Centre, 950 West 28 th Ave, Vancouver, BC, V5Z 4H4, Canada



CURRENT POSITION :

- ◆ Professor of Pediatrics, University of British Columbia

EDUCATIONAL BACKGROUND :

- ◆ B.A. Middlebury College
- ◆ M.D. Columbia University

RESEARCH INTERESTS :

- ◆ Bacterial pathogenesis of *Burkholderia cepacia* complex
- ◆ Molecular epidemiology of bacterial infections in cystic fibrosis
- ◆ Mechanisms of inflammation in auto-inflammatory disorders
- ◆ Effects of HIV exposure in utero to infants in the first two years of life

PUBLISHED WORKS : (in last 10 years)

- Wong SYC, Guerdoud LM, Cantin A, **Speert DP**. Glucose stimulates phagocytosis of unopsonized *Pseudomonas aeruginosa* by cultivated human alveolar macrophages. *Infect. Immun.* 67(1): 16-21, 1999
- Henry D, Campbell M, McGimpsey C, Clarke A, Loudon L, Burns JL, Roe MH, Vandamme P, **Speert DP**. Comparison of isolation media for recovery of *Burkholderia cepacia* complex from respiratory secretions of patients with cystic fibrosis. *J. Clin. Microbiol.* 37: 1004-1007, 1999
- Bryan R, Feldman M, Jawetz SC, Rajan S, DiMango E, Tang HB, Scheffler L, Speert DP, Prince A. The effects of aerosolized dextran in a mouse model of *Pseudomonas aeruginosa* pulmonary infection. *J. Infect. Dis.* 179(6): 1449-1458, 1999 June
- Speert DP, Simpson DA. Phagocytosis of *Pseudomonas aeruginosa*, In *Advances in Cell and Molecular Biology of Membranes and Organelles*" Gordon & Tartakoff (ed.) JAI Press, Inc. Vol. 6 pp. 159-172, 1999
- **Speert DP**, Steen B, Halsey K, Kwan E. A murine model for infection with *Burkholderia cepacia* with sustained persistence in the spleen. *Infect. Immun.* 67(8): 4027-4032, 1999 Aug
- Hirakata Y, Finlay BB, Kohno S, Kamihira S, **Speert DP**. Penetration of clinical isolates of *Pseudomonas aeruginosa* through MDCK epithelial cell monolayers. *J. Infect. Dis.* 181(2): 765-769, 2000 Feb
- Vandamme P, Mahenthiralingam E, Holmes B, Coenye T, Hoste B, de Vos P, Henry D, **Speert DP**. Identification and population structure of *Burkholderia stabilis* sp. nov (formerly *Burkholderia cepacia* genomovar IV). *J. Clin. Microbiol.* 38(3): 1042-1047, 2000 March
- Finlay WH, Lange CF, King M, **Speert DP**. Lung delivery of aerosolized dextran. *Am. J. Resp. Crit. Care Med.* 161(1): 91-97, 2000 Jan
- Aaron S, Ferris W, Henry DA, **Speert DP**, MacDonald N. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with *Burkholderia cepacia*. *Am. J. Resp. Crit. Care Med.* 161(4 Pt 1): 1206-1212, 2000 April



The 6th Congress of Asian Society for Pediatric Research & 51st Annual Meeting of Taiwan Pediatric Association

April 15-18, 2010 Taipei, Taiwan



- Simpson DA, **Speert DP**. RpmA is required for nonopsonic phagocytosis of *Pseudomonas aeruginosa*. *Infect. Immun.*, 68(5): 2493-2502, 2000 May
- Cheung DOY, Halsey K, **Speert DP**. Role of pulmonary alveolar macrophages in defense of the lung against *Pseudomonas aeruginosa*. *Infect. Immun. IAI* 68(8):4585-4592, 2000 Aug
- Campbell M, Mahenthalingam E, **Speert DP**. Evaluation of Random Amplified Polymorphic DNA Typing of *Pseudomonas aeruginosa*. *J. Clin. Microbiol* 38: 4614-4615, 2000
- Hancock REW, **Speert DP**. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and impact on treatment options (minireview). *Drug Resistance Updates* 3: 247-255, 2000
- Mahenthalingam E, Coenye T, Chung JW, **Speert DP**, Govan JRW, Taylor, Vandamme P. A diagnostically and experimentally useful panel of strains from the *Burkholderia cepacia* complex. *J. Clin. Microbiol.* 38: 910-913, 2000
- Saiman L, MacDonald N, Burns JL, Hoiby N, **Speert DP**, Weber D. Infection control in cystic fibrosis: Practical recommendations for the hospital, clinic, and social settings. *Am J Infect Control.* 28(5): 381-5, 2000 Oct
- **Speert DP**. Understanding *Burkholderia cepacia*: genomovars, virulence and epidemics. *Infections in Medicine. Infections in Medicine.* 18: 49-56, 2001
- Paluck E, Katzenstein D, Frankish CJ, Herbert C, Milner R, **Speert DP**, Chambers K. Prescribing practices and attitudes toward giving children antibiotics. *Canadian Family Physician.* 47: 521-527, 2001 March
- Pollard AJ, Heale JP, Tsang A, Massing B, **Speert DP**. Nonopsonic phagocytosis of *Pseudomonas aeruginosa*: insights from an infant with leucocyte adhesion deficiency. *Ped. Infect. Dis. J.*, 20(4):452-454, 2001 April
- Coenye T, Mahenthalingam E, Henry D, LiPuma JL, Laevens S, Gillis M, **Speert DP**, Vandamme P. *Burkholderia ambifaria* sp. nov., a novel member of the *Burkholderia cepacia* complex including biocontrol and cystic fibrosis-related isolates. *International Journal of Systemic and Evolutionary Microbiology.* 51(Pt 4):1481-1490, 2001 July
- Henry DA, Mahenthalingam E, Vandamme P, Coenye T, **Speert DP**. Phenotypic methods for determining genomovar status of the *Burkholderia cepacia* complex. *J. Clin. Microbiol.* 39(3): 1073-1078, 2001 March
- Henry DA, Mahenthalingam E, Vandamme P, Coenye T, **Speert DP**. Phenotypic methods for determining genomovar status of the *Burkholderia cepacia* complex. *J. Clin. Microbiol.* 39(3): 1073-1078, 2001 March
- Chiu CH, Ostry A, **Speert DP**. Invasion of murine respiratory epithelial cells in vivo by *Burkholderia cepacia*. *J. Med. Microbiol.* 50(7):594-601, 2001 July
- Heale JP, **Speert DP**. Protein kinase C agonists enhance phagocytosis of *P. aeruginosa* by murine alveolar macrophages. *J. Leuk. Biol.* 69(1): 158-160, 2001 Jan
- Coenye T, LiPuma JJ, Henry D, Hoste B, Vandemeulebroecke K, Gillis M, **Speert DP**, Vandamme P. *Burkholderia cepacia* genomovar VI, a new member of the *Burkholderia cepacia* complex isolated from cystic fibrosis patients. *Int. J. Syst. Evol. Microbiol.* 51(Pt 2): 271-279, 2001 March
- Heale JP, Pollard A, Crookall K, Stokes, RW, Simpson D, Tsang A, Massing B, **Speert DP**. Two distinct receptors mediate nonopsonic phagocytosis of different strains of *Pseudomonas aeruginosa*. *J. Infect. Dis.* 183(8): 1214-20, 2001 April
- Mahenthalingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LTK, Davidson AGF, Wilcox PG, Nakielna B, **Speert DP**. Infection with *Burkholderia cepacia* complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace *Burkholderia multivorans*. *Clin. Infect. Dis.* 33(9):1469-1475, 2001 Nov
- Chiu CH, Wong S, Hancock REW, **Speert DP**. Adherence of *Burkholderia cepacia* to respiratory tract epithelial cells and inhibition with dextrans. *Microbiol.* 147(Pt 10):2651-2658, 2001 Oct
- Greenberg D, **Speert DP**, Mahenthalingam E, Henry DA, Campbell ME, Scheifele DW. Emergence of Penicillin-Non-Susceptible Streptococcus Pneumoniae Invasive Clones In Canada. *J. Clin. Microbiol.* 40(1): 68-74, 2002 Jan
- **Speert DP**, Henry D, Vandamme P, Corey M, Mahenthalingam E. Epidemiology of *Burkholderia cepacia* in Patients with Cystic Fibrosis in Canada: Geographical Distribution and Clustering of Strains. *Emerg. Infect. Dis.* 8(2):181-187, 2002 Jan
- Chu KK, Davidson DJ, Halsey TK, Chung JW, **Speert DP**. Differential persistence among Genomovars of the *Burkholderia cepacia* complex in a murine model of pulmonary infection. *Infect. Immun.* 70(5):2715-2720, 2002 May
- Pollard AJ, Probe G, Trombley C, Castell A, Whitehead S, Bigham JM, Champagne S, Isaac-Renton J, Tan R, Guiver M, Borrow R, **Speert DP**, Thomas E. Evaluation of a diagnostic Polymerase Chain Reaction Assay for Neisseria meningitidis in North America and field experience during an outbreak. *Archives of Pathology & Laboratory Medicine.* 126(10): 1209-1215, 2002 Oct
- Vandamme P, Henry D, Coenye T, Nzula S, Vancanneyt M, LiPuma JJ, **Speert DP**, Govan JRW, Mahenthalingam E. *Burkholderia anthina* sp. nov. and *Burkholderia pyrrocinia*, two additional *Burkholderia cepacia* complex bacteria, may confound test results of new molecular diagnostic tools. *FEMS Immunology and Medical Microbiology.* 33(2):143-149, 2002 June



The 6th Congress of Asian Society for Pediatric Research & 51st Annual Meeting of Taiwan Pediatric Association

April 15-18, 2010 Taipei, Taiwan



- **Speert DP**, Campbell, ME, Henry DA, Milner R, Taha F, Gravelle A, Davidson AGF, Wong LTK, Mahenthalingam E. Epidemiology of *Pseudomonas aeruginosa* Infection in Patients with Cystic Fibrosis in British Columbia Canada: Low Risk of Patient to Patient Spread.” American Journal of Respiratory and Critical Care Medicine. 166:988-993, 2002.
- **Speert DP**, Molecular epidemiology of *Pseudomonas aeruginosa*. Frontiers in Bioscience. 7:e354-61 2002 Oct.
- Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, Kamihira S, Hancock, REW, **Speert DP**. Multidrug efflux plays an important role in the invasiveness of *Pseudomonas aeruginosa*. J. Exp. Med. 196(1):109-118, 2002 July.
- Soni R, Marks G, Henry DA, Robinson M, Moriarty C, Parsons S, Taylor P, Mahenthalingam E, **Speert DP**, Bye PT. Effect of *Burkholderia cepacia* infection in the clinical course of patients with cystic fibrosis: A pilot study in a Sydney clinic. Respiriology. 7(3): 241-245, 2002 Sep
- Conway BA, Venu V, **Speert DP**. Biofilm formation and acyl-homoserine lactone production in the *Burkholderia cepacia* complex. J. Bacteriol. 184(20): 5678-5685, 2002 Oct
- **Speert DP**. Advances in *Burkholderia cepacia* complex. Paediatric Respiratory Reviews. 3(3)230-235, 2002 Sep
- **Speert DP**. Self Assessments. Short Care Assessments. Paediatric Respiratory Reviews 3(3)274, 2002.
- Eftekhari F, Rostamizadeh F, Khodadad A, Henry D, **Speert, DP**. Isolation and genetic fingerprinting of *Pseudomonas aeruginosa* from Iranian patients with cystic fibrosis using RAPD-PCR. Iranian Journal of Biotechnology. 1: 95-100, 2003.
- Chung JW, Altman E, Beveridge TJ, **Speert DP**. Colonial Morphology of *Burkholderia cepacia* Complex Genomovar III: Implications in Exopolysaccharide Production, Pilus Expression and Persistence in the Mouse. Infection and Immunity. 71(2): 904-909, 2003 Feb.
- Currie AJ, **Speert DP**, Davidson DJ. *Pseudomonas aeruginosa*: a role in the pathogenesis of the CF lung lesion. Seminars in Respirator and Critical Care Medicine. 24(6): 671-680, Dec 2003
- Davidson DJ, Currie AJ, Reid GSD, Bowdish DME, MacDonald KL, Ma RC, Hancock REW, **Speert DP**. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunology. 172(2):1146-1156, 2004
- Currie AJ, Davidson DJ, Reid GSD, Bharya S, MacDonald KL, Devon RS, **Speert DP**. Primary immunodeficiency to pneumococcal infection due to a defect in toll-like receptor signaling. J. Pediatr. 144(4):512-518, 2004 April.
- Campsall PA, Au N, Prendiville JS, **Speert DP**, Tan R, Thomas EE. Detection and Genotyping of Varicella-Zoster Virus by Taqman Allelic Discrimination Real-Time PCR. J. Clin. Microbiol. 42(4):1409-1413, 2004 April
- Pollard AJ, Currie A, Rosenberger CM, Heale JP, Finlay BB, **Speert DP**. Differential post-transcriptional activation of human phagocytes by different *Pseudomonas aeruginosa* isolates. Cellular Microbiology. 6(7):639-650, 2004
- **Speert DP**, Goldberg JB. *Burkholderia cepacia* complex and cystic fibrosis: in search of the smoking gun. Am. J. Resp. Crit. Care Med. (editorial). 170(1): 6-7, 2004
- Bowdish DME, Davidson DJ, **Speert DP**, Hancock REW. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 172(6):3758-3765, 2004
- Conway BA, Chu KK, Bylund J, Altman E, **Speert DP**. Production of exopolysaccharide by *Burkholderia cenocepacia* results in altered cell-surface interactions and altered bacterial clearance in mice. J. Infect. Dis. 190(5):957-966, 2004.
- Chu KK, MacDonald KL, Davidson DJ, **Speert DP**. Persistence of *Burkholderia multivorans* within the pulmonary macrophage in the murine lung. Infect. Immun. 72(10):6142-7, Oct 2004.
- Coenye T, Henry D, **Speert DP**, Vandamme P. *Burkholderia phenoliruptrix* sp. nov., to accommodate the 2,4,5-trichlorophenoxyacetic acid and halophenol-degrading strain AC1100. Systemic and Applied Microbiology. 27(6): 623-627, 2004 Nov
- Bylund J, Campsall PA, Ma RC, Conway BA, **Speert DP**. *Burkholderia cenocepacia* induces neutrophil necrosis in chronic granulomatous disease. J. Immunol. 174(6):3562-3569, 2005Mar15.
- Husain E, Whitehead S, Castell A, Thomas EE, **Speert DP**. Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility. Pediatr. Infect. Dis. J., 24(6):563-566, 2005 June
- Lewis DA, Jones A, Parkhill J, **Speert DP**, Govan JR, LiPuma JJ, Lory S, Webb AK, Mahenthalingam E. Identification of DNA markers for a transmissible *Pseudomonas aeruginosa* cystic fibrosis strain. American Journal of Respiratory Cell and Molecular Biology 33(1):56-64, 2005July
- Mansouri D, Adimi P, Mirsaedi M, Mansouri N, Tabarsi P, Amiri M, Jamaati HR, Motavasseli M, Baghaei N, Cheraghvandi A, Rouhi R, Roozbahany NA, Zahirifard S, Mohammadi F, Masjedi R, Velayati AA, Casanova JL, **Speert DP**, Elwood RK, Schellenberg R, Turvey SE. Primary immune deficiencies presenting in adults: seven years of experience from Iran. J Clin Immunol. 2005 Jul;25(4):385-91



The 6th Congress of Asian Society for Pediatric Research & 51st Annual Meeting of Taiwan Pediatric Association

April 15-18, 2010 Taipei, Taiwan



- Baldwin A, Mahenthiralingam, Thickett KM, Honeybourne D, Maiden MCJ, Govan JR, **Speert DP**, LiPuma JJ, Vandamme P, Dowson CG. Multilocus sequence typing scheme that provides both species and strain differentiation for *Burkholderia cepacia* complex. J. Clin. Microbiol. 43(9):4665-4673, 2005 Sep
- Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, Senechal B, Plaucouline S, Al-Hajjar S, Al-Ghoniaum A, Marodi L, Davidson D, **Speert DP**, Roifman C, Garty BZ, Ozinsky A, Barratt FJ, Coffman RL, Miller RL, Li X, Lebon P, Rodriguez-Gallego CR, Chapel H, Geissmann F, Jouanguy E, Casanova JL. Human TLR-7, -8 and -9-mediated induction of IFN- α/β and lambda is IRAK-4-dependent and redundant for protective immunity to viruses. Immunity 23(5):465-478, 2005 Nov.
- Yoon SS, Coakley R, Lau GW, Lymar SV, Gaston B, Karabulut AC, Hennigan RF, Hwang SH, Buettner G, Schurr MJ, Mortensen JE, Burns JL, **Speert DP**, Boucher RC, Hassett DJ. Anaerobic killing of mucoid *Pseudomonas aeruginosa* by acidified nitrite derivatives under cystic fibrosis airway conditions. J. Clin. Invest. 2006 Feb;116(2):436-46
- Khashu M, Osioviich H, Henry D, Al Khotani A, Solimano A, **Speert DP**. Persistent bacteremia and severe thrombocytopenia caused by coagulase negative Staphylococcus in a neonatal intensive care unit. Pediatrics 117(2):340-348, 2006 Feb
- Bylund J, Burgess LA, Cescutti P, Ernst R, **Speert DP**. Exopolysaccharides from *Burkholderia cenocepacia* inhibit neutrophil chemotaxis and scavenge reactive oxygen species. J. Biol. Chem. 2006 Feb 3;281(5):2526-32
- Jacobson M, Wray R, Kovach D, Henry D, **Speert DP**, Matlow A. Sustained endemicity of *Burkholderia cepacia* complex in a pediatric institution, associated with contaminated ultrasound gel. Infection Control and Hospital Epidemiology. 27(4):362-366, April 2006
- Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, **Speert DP**, Moskowitz SM, Burns JL, Kaul R, Olson MV. Genetic adaptation by *Pseudomonas aeruginosa* to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A. 103(22): 8487-8492, May 30, 2006
- Davidson DJ, Currie AJ, Bowdish DME, Brown KL, Rosenberger CM, Ma RC, Bylund J, Campsall P, Puel A, Picard C, Casanova JL, Turvey SE, Hancock REW, Devon RS, **Speert DP**. IRAK-4 Mutation (Q293X): Rapid Detection and Characterization of Defective Post-transcriptional TLR/IL-1R Responses in Human Myeloid and Non-myeloid cells. J. Immunol. 2006 Dec 1;177(11):8202-11
- Chung JW, **Speert DP**. Proteomic identification and characterization of bacterial factors associated with *Burkholderia cenocepacia* survival in a murine host. Microbiology Jan 2007;153(Pt 1): 206-214
- Baldwin A, Mahenthiralingam E, Drevinek P, Vandamme P, Govan JR, Waime DJ, LiPuma JJ, Chiarini L, Dalmastrri C, Henry DA, **Speert DP**, Honeybourne D, Maiden MCJ, Dowson CG. Environmental *Burkholderia cepacia* complex Isolates in Human Infections. Emerging Infectious Diseases. 2007 March; 13(3):458-61
- Bylund J, MacDonald KL, Brown KL, Mydel P, Collins LV, Hancock REW, **Speert DP**. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kB. European Journal of Immunology. 2007 April;37(4):1087-96
- Waime DJ, Henry DA, Baldwin A, **Speert DP**, Honeybourne D, Mahenthiralingam E, Dowson CG. Reliability of multilocus sequence typing of the *Burkholderia cepacia* complex in cystic fibrosis. Journal of Cystic Fibrosis. 2007 May;6(3):215-9
- Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, **Speert DP**, Burns JL, Miller, SI. Unique Lipid A Modifications in *Pseudomonas aeruginosa* Isolated from the Airways of Patients with Cystic Fibrosis. The Journal of Infectious Diseases. October 2007; 196(7):1088-92
- Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, Chrabieh M, Issekutz AC, Cunningham CK, Gallin J, Holland SM, Roifman C, Ehl S, Smart J, Tang M, Barrat FJ, Levy O, McDonald D, Day-Good NK, Miller R, Takada H, Hara T, Al-Hajjar S, Al-Ghoniaum A, **Speert DP**, Sanlaville D, Li X, Geissmann F, Vivier E, Marodi L, Garty BZ, Chapel H, Rodriguez-Gallego C, Bossuyt X, Abel L, Puel A, Casanova JL. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J. Exp. Medicine; 204(10):2407-2422, October 2007
- Baldwin A, Mahenthiralingam E, Drevinek P, Pope C, Waime DJ, Henry DA, **Speert DP**, Carter P, Vandamme P, LiPuma JJ, Dowson CG. Elucidating Global Epidemiology of *Burkholderia multivorans* in Cases of Cystic Fibrosis by Multilocus Sequence Typing. J. Clin. Microbiol; 46(1):290-5, January 2008
- Zlosnik JEA, Hird TJ, Fraenkel MC, Moreira LM, Henry DA, **Speert DP**. Differential mucoid exopolysaccharide production by members of the *Burkholderia cepacia* complex. J. Clin. Microbiol; 46(4):1470-3, April 2008
- Vanlaere E, LiPuma JJ, Baldwin A, Henry DA, De Brandt E, Mahenthiralingam E, **Speert DP**, Dowson C, Vandamme P. *Burkholderia latens* sp. nov., *Burkholderia diffusa* sp. nov., *Burkholderia arboris* sp. nov., *Burkholderia seminalis* sp. nov., *Burkholderia metallica* sp. nov., novel species within the *Burkholderia cepacia* complex. Int'l Journal Syst Evol Microbiol; 58(7):1580-90, July 2008



The 6th Congress of Asian Society for Pediatric Research & 51st Annual Meeting of Taiwan Pediatric Association

April 15-18, 2010 Taipei, Taiwan



- MacDonald KL, **Speert DP**. Differential modulation of innate immune cell functions by the *Burkholderia cepacia* complex: *Burkholderia cenocepacia* but not *Burkholderia multivorans* disrupts maturation and induces necrosis in human dendritic cells. *Cellular Microbiology*; 10(10):2138-2149, 2008
 - Brown KL, Bylund J, MacDonald KL, Song-Zhao GX, Elliott MR, Falsafi R, Hancock REW, **Speert DP**. ROS-deficient Monocytes have Aberrant Gene Expression that Correlate with Inflammatory Disorders of Chronic Granulomatous Disease. *Clinical Immunology*; 129(1):90-102, 2008
 - Mena A, Smith EE, Burns JL, **Speert DP**, Moskowitz SM, Perez JL, Oliver A. Genetic Adaptation of *Pseudomonas aeruginosa* to the Airways of Cystic Fibrosis Patients is Catalyzed by Hypermutation. *Journal of Bacteriology*; 190(24):7910-7917, 2008
 - Vanlaere E, Baldwin A, Gevers D, Henry DA, De Brandt E, LiPuma JJ, Mahenthiralingam E, **Speert DP**, Dowson C, Vandamme P. Taxon K, a complex within the *Burkholderia cepacia* complex comprises at least two novel species: *Burkholderia vanimaris* sp. nov. and *Burkholderia lata* sp. nov. *Int'l Journal Syst Evol Microbiol.*; 59(Pt 1):102-111, 2009
 - Eftekhari F, **Speert DP**. Biofilm formation by persistent and non-persistent isolates of *Staphylococcus epidermidis* from a neonatal intensive care unit. *Journal of Hospital Infection*; 71(2):112-116, 2009
 - Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald KL, **Speert DP**, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, Hornung V, Latz E. NF- κ B activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. *J Immunol*; 183:787-791, 2009
 - Hickey TBM, Thorson LM, **Speert DP**, Dafee M, Stokes RW. *Mycobacterium tuberculosis* Cpn60.2 and DnaK are located on the bacterial surface, where Cpn60.2 facilitates efficient bacterial association with macrophages. *Infection & Immunity*; 77(8):3389-3401, 2009
-